PATENT CLAIM ANALYSIS

Application Number: 16225772
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["514", "318000"]

Abstract:
The present invention provides a therapeutic agent for bile duct cancer comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxy)-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or a pharmacologically acceptable salt thereof.

Claim (Index 19):
The method according to  claim 13 , wherein the gene encoding the FGFR 2-fusion protein is FGFR2-BICC1 type 2.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 98.0
- Lexical Diversity: 1.34375
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13889337', '14329639', '15108014', '14183864', '15500429']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7582285792046497
- 35 USC 102 Novelty (BERT): 0.5057148504300663
- Combined Prediction Score: 0.7329772063271913
- Mean Citation Score: 212.567382
- Max Citation Score: 225.49341
- Similarity Product: 142.96936819405676

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test